Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience
Bergeron C, Jenney M, De Corti F, Gallego S, Merks JHM, Glosli H, Ferrari A, Ranchère-Vince D, De Salvo GL, Zanetti I, Chisholm J, Minard-Colin V, Rogers T, Bisogno G. on behalf of the European paediatric Soft tissue sarcoma Study Group (EpSSG). European Journal of Cancer, Vol 146, March 2021, 21-29. https://doi.org/10.1016/j.ejca.2020.12.025
Abstract Background Rhabdomyosarcoma (RMS) is the most common form of soft tissue sarcoma in…
Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups.
Gallego S, Chin YY, Zanetti I, Li M, Merks JHM, Rodeberg DA, van Scheltinga ST, Mascarenhas L, Orbach D, Jenney M, Million L, Minard-Colin V, Wolden S, De Salvo GL, Parham D, Mandeville H, Venkatramani R, Bisogno G, Hawkins DS. Pediatr Blood Cancer. 2020 Nov 27; e28832. doi: 10.1002/pbc.28832.
Abstract Background: Treatment of children and adolescents with alveolar rhabdomyosarcoma (ARMS) and…
Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG-RMS2005 study
Terwisscha van Scheltinga S, Marc H. W. A. Wijnen MHWA, Martelli H, Rogers T, Mandeville H, Gaze MN, McHugh K, Corradini N, Orbach D, Jenney M, Kelsey A, Chisholm J, Gallego S, Glosli H, Ferrari A, Zanetti I, De Salvo GL, Minard-Colin V, Bisogno G, van Noesel M, Merks JHM. Cancer Med. 2020 Oct;9(20):7580-7589. doi: 10.1002/cam4.3365.
Abstract Rhabdomyosarcoma of the extremities present with two main challenges: correct evaluation of…
Surgical Management of Extremity Rhabdomyosarcoma: A Consensus Opinion from the Children’s Oncology Group, European Pediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe
Morris CD, Tunn P, Rodeberg DA, van Scheltinga ST, Binitie O, Godzinski J, Dall'Igna P, Million L, Hawkins DS, Koscielniak E, Bisogno G, Rogers T. Pediatr Blood Cancer 2020 Aug 9;e28608. doi: 10.1002/pbc.28608.
Abstract The treatment of extremity rhabdomyosarcoma remains a challenge due to several adverse…
Paratesticular rhabdomyosarcoma-Impact of Locoregional Approach on Patient Outcome: A Report From the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
Rogers T, De Corti F, Guillén Burrieza G, Guérin F, van Scheltinga ST, Smeulders N, Craigie R, Jenney M, Kelsey A, Zanetti I, Coppadoro B, De Salvo GL, Bisogno G, Martelli H. Pediatr Blood Cancer. 2020 Jun 23:e28479. doi: 10.1002/pbc.28479.
Abstract Background: Paratesticular rhabdomyosarcoma (PT RMS) is rare compared to benign scrotal…
Spotlight on the treatment of infantile fibrosarcoma in the era of neutrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies.
Orbach D, Sparber-Sauer M, Laetsch TW, Minard-Colin V, Bielack SS, Casanova M, Corradini N, Koscielniak E, Scheer M, Hettmer S, Bisogno G, Hawkins D, Ferrari A. EJC of Cancer 137 (2020) 183-192.
Abstract Targeted neurotrophic tropomyosin receptor kinase (TRK) inhibitors offer a highly specific…
Dermatofibrosarcoma Protuberans in children and adolescents: the European Paediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005)
Brennan B, Zanetti I, De Salvo GL, Orbach D, Gallego S, Francotte N, Schifflers S, van Noesel M, Kelsey A, Casanova M, Dagrada GP, Collini P, Zin A, Santoro L, Ferrari A. Pediatr Blood Cancer. 2020 Jun 18;e28351. doi: 10.1002/pbc.28351
Abstract Background As dermatofibrosarcoma protuberans (DFSP) are rare with no prospective series…
Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy.
Ferrari A, Merks JHM, Chisholm JC, Orbach D, Brennan B, Gallego S, van Noesel MM, McHugh K, van Rijn RR, Gaze MN, Martelli H, Bergeron C, Corradini N, Minard-Colin V, Bisogno G, Geoerger B, Caron HN, De Salvo GL, Casanova M. Eur J Cancer. 2020 Mar 13;130:72-80. doi: 10.1016/j.ejca.2020.01.029.
Abstract Purpose: We analysed the cohort of paediatric patients with metastatic non-rhabdomyosarcoma…
A new standard of care for patients with high-risk rhabdomyosarcoma?
Bisogno G, Ferrari F, Gallego Melcon S, De Salvo GL, Bergeron C, Jenney M. The Lancet Oncol, Correspondence letter, Vol 21 Jan 2020
Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Casanova M, Brennan B, Alaggio R, Kelsey A, Orbach D, van Noesel MM, Corradini N, Minard-Colin V, Zanetti I, Bisogno G, Gallego S, Merks JHM, De Salvo GL, Ferrari A. Eur J Cancer. 2020 Jan 30;127:123-129. doi: 10.1016/j.ejca.2019.12.021.
Abstract Introduction: We report the clinical findings and results of treatment in the cohort of…
Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience.
Vaarwerk B, Mallebranche C, Affinita MC, van der Lee JH, Ferrari A, Chisholm JC, Defachelles AS, De Salvo GL, Corradini N, Minard-Colin V, Morosi C, Brisse HJ, McHugh K, Bisogno G, van Rijn RR, Orbach D, Merks JHM, Cancer. 2019 Nov 21. doi: 10.1002/cncr.32603.
Abstract Background After the completion of therapy, patients with localized rhabdomyosarcoma (RMS)…
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high risk rhabdomyosarcoma (RMS 2005): a multicentre, open label, randomized phase 3 trial.
Bisogno G, De Salvo GL, Bergeron C, Gallego S, Merks JHM, Kelsey A, Martelli H, Minard-Colin V, Orbach D, Glosli H, Chisholm J, Casanova M, Zanetti I, Devalck C, Ben Arush M, Mudry P, Ferman S, Jenney M, Ferrari A. Lancet Oncol. 2019 Sept 24. https://doi.org/S1470-2045(19)30617-5.
Abstract Background: For more than three decades, standard treatment for rhabdomyosarcoma in Europe…
Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS‐2005 prospective study
Van Noesel MM, Orbach D, Brennan B, Kelsey A, Zanetti I, De Salvo GL, Gaze MN, Craigie RJ, McHugh K, Francotte N, Collini P, Bisogno G, Casanova M, Ferrari A. Pediatr Blood Cancer. 2019 Jun 26:e27833. doi: 10.1002/pbc.27833. [Epub ahead of print]
Abstract Background Malignant peripheral nerve sheath tumors (MPNST) are rare tumors of childhood.…
Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children’s Oncology Group (COG) and the European paediatric soft tissue Sarcoma Study Group (EpSSG) prospective clinical trials
Spunt S, Francotte N, De Salvo GL, Chi YY, Zanetti I, Hayes-Jordan A, Kao S, Orbach D, Brennan B, Weiss A, Van Noesel M, Million L, Alaggio R, Parham D, Kelsey A, Randall RL, McCarville MB, Bisogno G, Hawkins D, Ferrari A, EIC Eur J Cancer. 2019 Apr 4;112:98-106. DOI: 10.1016/j.ejca.2019.02.001.
Abstract Background: Data on the clinical features, optimal treatment and outcomes of paediatric…
Outcome of localized liver-bile duct rhabdomyosarcoma according to local therapy. A report from the European paediatric Soft Tissue Sarcoma Study Group (EpSSG)- RMS 2005 study.
Guerin F, Rogers T, Minard-Colin V, Gaze M, Terwisscha S, van Noesel M, De Corti F, Guillen Burrieza G, De Salvo GL, Kelsey A, Orbach D, Ferrari A, Bergeron C, Bisogno G, Martelli H, Pediatr Blood Cancer. 2019 Mar 28:e27725. DOI: 10.1002/pbc.27725
Abstract Objectives To evaluate the impact of local therapies on the outcome of patients with…
Indeterminate pulmonary nodules at diagnosis in pediatric rhabdomyosarcoma: are we undertreating patients? A report from the European paediatric Soft tissue sarcoma Study Group-RMS-2005 protocol.
Vaarwerk B, Bisogno G, McHugh K, Brisse H, Morosi C, Corradini N, Jenney M, Orbach D, Chisholm J, Ferrari A, Zanetti I, De Salvo GL, Van Rijn RR, Merks JHM, EpSSG Radiology Group. J Clin Oncol. 2019 Jan 31:JCO1801535. DOI: 10.1200/JCO.18.01535
Abstract Purpose To evaluate the clinical significance of indeterminate pulmonary nodules at…
Localized vaginal/uterine rhabdomyosarcoma-results of a pooled analysis from four international cooperative groups.
Minard-Colin V, Walterhouse D, Bisogno G, Martelli H, Anderson J, Rodeberg DA, Ferrari A, Jenney M, Wolden S, De Salvo G, Arndt C, Merks JHM, Gallego S, Schwob D, Haie-Meder C, Bergeron C, Stevens MCG, Oberlin O, Hawkins D; International Society of Pediatric Oncology Sarcoma Committee, the Children's Oncology Group, the Italian Cooperative Soft Tissue Sarcoma Group, and the European pediatric Soft tissue sarcoma Study Group. Pediatr Blood Cancer. 2018 Sep;65(9):e27096. DOI: 10.1002/pbc.27096.
Abstract Background Vaginal/uterine rhabdomyosarcoma (VU RMS) is one of the most favorable RMS…
Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results from a Pooled-Analysis of North American and European Cooperative Groups
Walterhouse D, Barkauskas D, Hall D, Ferrari A, De Salvo GL, Koscielniak E, Stevens M, Martelli H, Seitz G, Rodeberg D, Shnorhavorian M, Dasgupta R, Breneman JC, Anderson JR, Bergeron C, Bisogno G, Meyer WH, Hawkins D, Minard-Colin V. J Clin Oncol. 2018 Oct 23:JCO2018789388. DOI: 10.1200/JCO.2018.78.9388.
Purpose Treatment recommendations for localized paratesticular rhabdomyosarcoma (PT RMS) differ in…
Fusion status in node-positive (n1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: the experience of the European paediatric soft tissue Sarcoma Study Group (EpSSG)
Gallego Melcón S, Zanetti I, Orbach D, Ranchère D, Shipley J, Zin A, Bergeron C, De Salvo GL, Chisholm J, Ferrari A, Jenney M, Mandeville HC, Rogers T, Merks JH, Mudry P, Glosli H, Milano GM, Ferman S, Bisogno G, on behalf of the EpSSG (European Paediatric Soft Tissue Sarcoma Study Group), Fusion status in node-positive (n1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: the experience of the European paediatric soft tissue Sarcoma Study Group (EpSSG). Cancer. 2018. DOI: 10.1002/cncr.31553.
Abstract BACKGROUND Alveolar rhabdomyosarcoma (aRMS) with lymph node involvement (N1 classification)…
The Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicenter, open-label, randomized controlled, phase 3 trial
Bisogno G, Jenney M, Bergeron C, Gallego Melcón S, Ferrari A, Oberlin O, Carli M, Stevens M, Kelsey A, De Paoli A, Gaze MN, Martelli H, Devalck C, Merks JH, Ben-Arush M, Glosli H, Chisholm J, Orbach D, Minard-Colin V, De Salvo GL, for the EpSSG. The Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicenter, open-label, randomized controlled, phase 3 trial. Lancet Oncol. 2018. pii: S1470-2045(18)30337-1. DOI: 10.1016/S1470-2045(18)30337-1
Abstract Background: Rhabdomyosarcoma is an aggressive tumour that can develop in almost any part of…
